Trending...
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
Download
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp's comprehensive, end-to-end drug development and clinical trial programs.
More on ncarol.com
HealthVerity's IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.'s largest ecosystem1 of health care and consumer data.
"This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines."
Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity's RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp's ability to be a trusted source of information for its clients.
"Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data," said Andrew Kress, CEO of HealthVerity. "Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client's applications of choice."
Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
More on ncarol.com
About HealthVerity
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com
1 Internal data from HealthVerity
2 Internal data from HealthVerity
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
Photo courtesy of Labcorp
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp® (NYSE: LH), a leading global life sciences company, today announced a new collaboration with HealthVerity, Inc., the leader in Identity, Privacy, Governance, and Exchange (IPGE) for real-world data (RWD), that will expand Labcorp's comprehensive, end-to-end drug development and clinical trial programs.
More on ncarol.com
- Preston Dermatology & Skin Surgery Center Wins Gold and Bronze in Prestigious Annual DIAMOND Awards
- David Boland, Inc. Awarded $54.3M Construction Contract by U.S. Army Corps of Engineers, Savannah District
- "Phinge Unveil™" Coming to Las Vegas to Showcase Netverse Patented Verified App-less Platform, AI & Modular Hardware Including Developer Conferences
- Elizabeth McLaughlin, Founder and CEO of Red Wagon Group, named 2026 Presidential Leadership Scholar
- U.S. Congressional Candidate Peter Coe Verbica on America's Asymmetric Crisis
HealthVerity's IPGE platform, an integrated technology and RWD infrastructure, enables Labcorp Drug Development and other participating companies to access fully interoperable, HIPAA-compliant data from the U.S.'s largest ecosystem1 of health care and consumer data.
"This collaboration allows Labcorp to expand existing end-to-end solutions for drug and diagnostics development, commercialization and clinical trial efforts to include large-scale access to real-world data for research applications," said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. "By applying advanced analytics, Labcorp can help its clients improve their processes and reach better outcomes. Our substantial repository of test results can also help study sponsors more quickly and accurately assess patient eligibility for clinical trials, enroll patients faster and accelerate the availability of new medicines."
Now more than ever, study sponsors are seeing the potential of RWD to yield longitudinal patient insights before, during and after trials. With more predictive analytics and artificial intelligence applications requiring comprehensive and fully interoperable RWD, Labcorp can align de-identified patient data with ten times greater accuracy2 than industry alternatives by using the HealthVerity IPGE platform. In addition, access to HealthVerity's RWD with on-demand de-identification and data linkage capabilities reinforces Labcorp's ability to be a trusted source of information for its clients.
"Fragmentation of patient data is at an all-time high, and the goal is no longer just connecting this data," said Andrew Kress, CEO of HealthVerity. "Rather, the goal is making data more accessible and useful for gaining a detailed understanding of patient journeys. With analytics and applications requiring more frictionless access to the data itself, the HealthVerity IPGE platform stands alone in offering the ability to combine transaction-level patient data in a de-identified, fully interoperable manner, and delivering it directly into the client's applications of choice."
Labcorp is an investor in HealthVerity through the Labcorp Venture Fund.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
More on ncarol.com
- Jones Sign Rebrands as Jones to Reflect Growth, Innovation, and Expanded Capabilities
- Helping high-functioning women reduce mental load by redesigning broken life systems
- $1 Million Share Repurchase Signals Confidence as Off The Hook YS Scales a Tech-Driven Platform in the $57 Billion U.S. Marine Market
- Trends Journal's Top Trends of 2026
- Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Healing, No Itch, and Vibrant Results
About HealthVerity
Pharmaceutical manufacturers, payers, and government organizations have partnered with HealthVerity to solve some of their most complicated use cases through transformative technologies and real-world data infrastructure. The HealthVerity IPGE platform, based on the foundational elements of Identity, Privacy, Governance, and Exchange, enables the discovery of real-world data across the broadest healthcare data ecosystem, the building of more complete and accurate patient journeys and the ability to power best-in-class analytics and applications with flexibility and ease. Together with our partners, HealthVerity has built the modern way to data for the health insights economy. To learn more about the HealthVerity IPGE platform, visit www.healthverity.com
1 Internal data from HealthVerity
2 Internal data from HealthVerity
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
0) { // Create container for hi-res image jQuery('#bw-release-hires').append('
'); }; }); ]]>
Contacts
Labcorp Contacts:
Media: Christopher Allman-Bradshaw — 336-436-8263
Media@Labcorp.com
Investors: Chas Cook — 336-436-5076
Investor@Labcorp.com
HealthVerity Media Contact:
Jennifer Kaczmarczyk
Vice President, Marketing
jkaczmarczyk@healthverity.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- Scoop Social Co. Partners with Air Canada to Celebrate New Direct Flights to Milan with Custom Italian Piaggio Ape Gelato Carts
- Breakout Phase for Public Company: New Partnerships, Zero Debt, and $20 Million Growth Capital Position Company for 2026 Acceleration
- Japan's Patented "Hammock'n" Smartphone Band Targets Hand Fatigue From Long Phone Use
- Reditus Group Introduces A New Empirical Model for Early-Stage B2B Growth
- CCHR: Harvard Review Exposes Institutional Corruption in Global Mental Health
- Goatimus Launches Dynamic Context: AI Prompt Engineering Gets Smarter
- Global License Exclusive Secured for Emesyl OTC Nausea Relief, Expanding Multi-Product Growth Strategy for Caring Brands, Inc. (N A S D A Q: CABR)
- RNHA Affirms Support for President Trump as Nation Marks Historic Victory for Freedom
- American Laser Study Club Announces 2026 Kumar Patel Prize in Laser Surgery Recipients: Ann Bynum, DDS, and Boaz Man, DVM
- Lineus Medical Completes UK Registration for SafeBreak® Vascular
- Canyons & Chefs Announces Revamped Homepage
- $140 to $145 Million in 2026 Projected and Profiled in New BD Deep Research Report on its Position in $57 Billion US Marine Industry; N Y S E: OTH
- Really Cool Music Releases Its Fourth Single - "So Many Lost Years"
- MGN Logistics Acquires Fast Service LLC, Fueling MyMGN Marketplace Expansion and Supercharging Expedited Coverage Nationwide
- The Wait is Over: Salida Wine Festival Announces Triumphant 2026 Return After Seven-Year Hiatus
- Graduates With $40K in Student Debt Are Buying Businesses Instead of Taking Entry-Level Jobs
- Tatt:Magic Unveils Breakthrough Tattoo Recovery System with Faster Recovery No Itch, for Vibrant ink
- Anne Seidman: Within the Lines
- How Democrats Made Healthcare More Expensive in 2026